

Product Datasheet

Ingliforib

Catalog No. **BP-01939** · CAS **186392-65-4** · Form **free base** · Physical state **solid** · Color **light yellow to yellow** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Phosphorylase	Research area Cardiovascular Disease
--------------------------------	--

Molecular formula **C₂₃H₂₄ClN₃O₅**

Molecular weight **457.9070**

STRUCTURE



DESCRIPTION

Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC₅₀s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.

BIOLOGICAL ACTIVITY

In Vitro

Ingliforib is a glycogen phosphorylase inhibitor, and inhibits the myocardial GP isoforms (muscle and brain) with IC₅₀s of 352 and 150 nM, respectively, also a potent inhibitor of the liver isoform (IC₅₀ of 52 nM). Ingliforib (0.1, 1, 10 μM) dose-dependently reduces infarct size in the isolated rabbit hearts.

In Vivo

Ingliforib (15 mg/kg) potently reduces infarct size by 52%, and decreases plasma glucose and lactate concentrations in openchest anesthetized rabbits. Ingliforib (15 mg/kg) also inhibits myocardial glycogen phosphorylase a (GP_a) and total glycogen phosphorylase (GP) activity in anesthetized rabbits.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Tracey WR, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1177-84.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.